Canadian biotechnology company Cardiome Pharma Corp. filed with U.S. regulators on Wednesday to periodically sell up to $150 million in common shares.

The company said in a registration statement with the Securities and Exchange Commission that it would use the proceeds from the shelf offering for working capital and other general corporate purposes, including clinical development and regulatory costs and acquisitions.

Under a shelf registration, a company may sell securities in one or more separate offerings, with the size, price and terms to be determined at the time of sale.